整合黄斑神经节细胞内丛状层与视盘旁视网膜神经纤维层测量以检测青光眼进展
前瞻性研究纳入136例原发性开角型青光眼患者(231眼)随访≥5年,每约4个月行OCT测量黄斑GCIPL和视盘旁RNFL厚度及视野检查。进展性GCIPL变薄与进展性RNFL变薄相互预测,且二者均与视野进展风险升高相关,提示整合黄斑GCIPL与视盘旁RNFL测量有助于早期发现青光眼恶化。
要点
- 进展性GCIPL变薄与进展性RNFL变薄相互预测(HR分别为5.27和2.99)。
- 检测到进展性GCIPL或RNFL变薄均与视野进展风险升高相关。
- 整合黄斑GCIPL与视盘旁RNFL测量有助于早期发现青光眼恶化。
核心结论
- 进展性黄斑GCIPL变薄与进展性视盘旁RNFL变薄相互预测。
- 进展性RNFL变薄和进展性GCIPL变薄均提示视野进展,整合黄斑GCIPL与视盘旁RNFL测量有助于早期发现青光眼患者的疾病恶化。
研究设计与样本
- 前瞻性研究,纳入136例原发性开角型青光眼患者共231眼,随访≥5年。
- 每约4个月行黄斑GCIPL和视盘旁RNFL的OCT成像及视野检查; progression由系列GCIPL和RNFL厚度图的引导进展分析(GPA)判定。
- GPA特异性由36名健康个体共67眼随访≥5年的进展性GCIPL或RNFL变薄比例计算。
- 视野进展(很可能或可能)由早期 manifest 青光眼试验(EMGT)标准判定。
主要发现
- GPA检测到57眼(24.7%)出现进展性GCIPL变薄,66眼(28.6%)出现进展性RNFL变薄,特异性分别为95.5%和91.0%。
- 35眼(15.2%)同时出现进展性RNFL和GCIPL变薄,53眼(22.9%)出现进展性RNFL或GCIPL变薄。
- 校正基线协变量后,有进展性GCIPL变薄的眼发生进展性RNFL变薄的风险更高(HR 5.27,95%CI 2.89-9.62);有进展性RNFL变薄的眼发生进展性GCIPL变薄的风险也更高(HR 2.99,95%CI 1.48-6.02)。
- 校正基线协变量后,检测到进展性GCIPL变薄时,很可能和可能视野进展的HR分别为3.48(95%CI 1.51-8.01)和2.74(95%CI 1.26-5.98)。
- 检测到进展性RNFL变薄时,很可能和可能视野进展的HR分别为3.66(95%CI 1.68-7.97)和2.54(95%CI 1.23-5.21);有视野进展的眼未处于进展性RNFL或GCIPL变薄的风险中(P≥0.493)。
临床怎么用
- 原文结论认为整合黄斑GCIPL与视盘旁RNFL测量有助于促进青光眼患者疾病恶化的早期检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the temporal relationship among progressive macular ganglion cell inner plexiform layer (GCIPL) thinning, progressive parapapillary retinal nerve fiber layer (RNFL) thinning, and visual field (VF) progression in patients with primary open-angle glaucoma (POAG). DESIGN: Prospective study. PARTICIPANTS: One hundred thirty-six POAG patients (231 eyes) followed up for ≥5 years. METHODS: OCT imaging of the macular GCIPL and parapapillary RNFL and perimetry were performed at ∼ 4-month intervals. Progressive GCIPL and RNFL thinning were determined by Guided Progression Analysis (GPA) of serial GCIPL and RNFL thickness maps. The specificities of GPA were calculated from the proportions of eyes with progressive GCIPL or RNFL thinning in 67 eyes of 36 healthy individuals followed up for ≥5 years. Visual field progression (likely or possible) was determined by the Early Manifest Glaucoma Trial criteria. MAIN OUTCOME MEASURES: Hazard ratios for VF progression, progressive RNFL thinning, and progressive GCIPL thinning, as determined by time-varying Cox models. RESULTS: GPA detected 57 eyes (24.7%) with progressive GCIPL thinning and 66 eyes (28.6%) with progressive RNFL thinning at a specificity of 95.5% and 91.0%, respectively. Thirty-five eyes (15.2%) demonstrated progressive RNFL and GCIPL thinning, whereas 53 eyes (22.9%) demonstrated progressive RNFL or GCIPL thinning. Eyes with progressive GCIPL thinning had a higher risk for progressive RNFL thinning (HR, 5.27; 95% confidence interval [CI], 2.89-9.62), whereas eyes with progressive RNFL thinning were also at a higher risk for progressive GCIPL thinning (HR, 2.99; 95% CI, 1.48-6.02), after adjusting for baseline covariates. The HRs for likely and possible VF progression were 3.48 (95% CI, 1.51-8.01) and 2.74 (95% CI, 1.26-5.98), respectively, on detection of progressive GCIPL thinning and 3.66 (95% CI, 1.68-7.97) and 2.54 (95% CI, 1.23-5.21), respectively, on detection of progressive RNFL thinning after adjusting for baseline covariates. Eyes with VF progression were not at risk of progressive RNFL or GCIPL thinning (P ≥ 0.493). CONCLUSIONS: Progressive macular GCIPL thinning and progressive parapapillary RNFL thinning are mutually predictive. Because progressive RNFL thinning and progressive GCIPL thinning are both indicative of VF progression, integrating macular GCIPL and parapapillary RNFL measurements is relevant to facilitate early detection of disease deterioration in glaucoma patients.
引用
- Hou HW, Lin C, Leung CK, et al. Integrating Macular Ganglion Cell Inner Plexiform Layer and Parapapillary Retinal Nerve Fiber Layer Measurements to Detect Glaucoma Progression. Ophthalmology. 2018. PMID: 29433852. doi:10.1016/j.ophtha.2017.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。